| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary targets of Thymus peptide C are the bone marrow and the lymphatic system. It acts by attracting immature systemic cells in the bone marrow and promoting their maturation to fully active T cells in the lymphatic system. It increases granulopoiesis and erythropoiesis by acting on the bone marrow. This immunomodulatory activity helps to enhance immune function and maintain immune homeostasis, substituting for the physiological functions of the thymus.
|
|---|---|
| ln Vitro |
Adrenocortical hormones' effects on the lymphatic system are countered by thymosin C. The physiological roles of the thymus can be substituted by thymosin C. Thymosin C attracts immature systemic cells in the bone marrow and promotes their maturation to the fully active T cell stage in the lymphatic system when T cells are insufficient. Thymosin C acts on the bone marrow to increase erythropoiesis and granulopoiesis. This formulation has been found to be effective in treating a wide range of conditions, including chronic viral, bacterial, and fungal infections; allergic and autoimmune reactions; proliferative syndrome of certain lymphoid tissues; and disorders of the primary and secondary immune systems that involve thymus-dependent T cells.
In vitro, Thymus peptide C is a hormonally active molecule that can substitute for the physiological functions of the thymus. It is used to study its effects on immune cell development and function. It promotes the maturation of T cells and enhances immune responses. Its activity is assessed by its ability to stimulate the proliferation and differentiation of T cells in culture. It is a valuable tool for studying thymic function and immune regulation. |
| ln Vivo |
In vivo, Thymus peptide C acts as a hormonal drug that enhances immune function. It increases granulopoiesis and erythropoiesis by acting on the bone marrow. It attracts immature systemic cells in the bone marrow and promotes their maturation to the fully active T-cell stage in the lymphatic system. It is used as an immunomodulatory agent to treat conditions associated with immune deficiency or dysfunction. It substitutes for the physiological functions of the thymus.
|
| Enzyme Assay |
Cell-free receptor binding assays for Thymus peptide C are not typical, as its mechanism involves complex cellular processes in the bone marrow and lymphatic system. However, its binding to immune cells can be studied. A protocol involves isolating thymocytes or bone marrow cells and incubating them with a labeled Thymus peptide C. The binding and internalization can be assessed by flow cytometry or fluorescence microscopy. This helps characterize its interaction with target cells.
|
| Cell Assay |
For in vitro cellular experiments, thymocytes or bone marrow cells are isolated from rodents and cultured in appropriate media. Cells are treated with Thymus peptide C at various concentrations (typically 0.1-100 ug/mL) for several days. T-cell proliferation and differentiation are assessed by measuring the expression of T-cell markers (e.g., CD3, CD4, CD8) using flow cytometry. Cytokine production is measured by ELISA. These experiments define its immunomodulatory effects.
|
| Animal Protocol |
In vivo animal experiments with Thymus peptide C are conducted in models of immune deficiency or to study its immunomodulatory effects. A common protocol involves administering the compound via subcutaneous or intraperitoneal injection to mice or rats at various doses (e.g., 1-50 mg/kg) for several days or weeks. The effects on the immune system are assessed by measuring blood cell counts, lymphocyte subsets, and cytokine levels. The compound's ability to enhance immune function and protect against infections is evaluated.
|
| ADME/Pharmacokinetics |
Thymus peptide C has a molecular weight of 1233.086 g/mol and is a small peptide. As a peptide, it is typically administered by injection. Its half-life in vivo is short due to proteolytic degradation. It is stable as a powder and should be stored at -20degC. It is soluble in aqueous buffers. Its pharmacokinetic properties are consistent with those of a peptide, characterized by rapid clearance. It is available as a research compound and as a pharmaceutical in some regions.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Thymus peptide C is considered favorable, as it is a naturally derived peptide used clinically. It is generally well-tolerated with a low incidence of adverse effects. As an immunomodulatory agent, it may cause immune-related side effects in some individuals. However, it is considered safe at therapeutic doses. It is for research use only and not for human therapeutic use in a research setting, though it is a pharmaceutical in some countries.
|
| Additional Infomation |
See also: Oil, Licorice (Notes have been moved to).
Thymus peptide C is a hormonal drug derived from the thymus glands of young calves. It acts as a substitute for the physiological functions of the thymus. It increases granulopoiesis and erythropoiesis by acting on the bone marrow and promotes T-cell maturation. It is used as an immunomodulatory agent to enhance immune function. It is a valuable research tool for studying thymic function and immune regulation. |
| Exact Mass |
1233.086
|
|---|---|
| CAS # |
316791-23-8
|
| PubChem CID |
161209287
|
| Appearance |
Colorless to light yellow liquid
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
88
|
| Complexity |
1190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1CCC(C(C1)C(=C)C)O.CC1CCC(C(C1)O)C(=C)C.CC1CCCC(C1C(=C)C)O.CC1CCCC(C1O)C(=C)C.CC1CCC(CC1C(=C)C)O.CC1CC(CC(C1)O)C(=C)C.CC1CC(CC(C1C=C)C)O.CC1C(CCCC1O)C(=C)C
|
| InChi Key |
UWADSUFAUYGJQM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/8C10H18O/c1-7(2)9-4-8(3)5-10(11)6-9;1-7(2)10-6-9(11)5-4-8(10)3;1-7(2)9-6-8(3)4-5-10(9)11;1-7(2)9-5-4-8(3)6-10(9)11;1-7(2)9-5-4-6-10(11)8(9)3;1-7(2)10-8(3)5-4-6-9(10)11;1-7(2)9-6-4-5-8(3)10(9)11;1-4-10-7(2)5-9(11)6-8(10)3/h7*8-11H,1,4-6H2,2-3H3;4,7-11H,1,5-6H2,2-3H3
|
| Chemical Name |
4-ethenyl-3,5-dimethylcyclohexan-1-ol;2-methyl-3-prop-1-en-2-ylcyclohexan-1-ol;2-methyl-6-prop-1-en-2-ylcyclohexan-1-ol;3-methyl-2-prop-1-en-2-ylcyclohexan-1-ol;3-methyl-5-prop-1-en-2-ylcyclohexan-1-ol;4-methyl-2-prop-1-en-2-ylcyclohexan-1-ol;4-methyl-3-prop-1-en-2-ylcyclohexan-1-ol;5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
